Literature DB >> 18401674

Immunological function of thymoma and pathogenesis of paraneoplastic myasthenia gravis.

Meinoshin Okumura1, Yoshitaka Fujii, Hiroyuki Shiono, Masayoshi Inoue, Masato Minami, Tomoki Utsumi, Yoshihisa Kadota, Yoshiki Sawa.   

Abstract

Thymoma and thymic carcinoma are the representative tumors arising from the thymic epithelium. Thymoma is well known for association with autoimmune diseases including myasthenia gravis, suggesting its biological activity. Herein, recent progress in research of thymoma is reviewed with reference to its immunological function. Myasthenia gravis is frequently associated with WHO type B1 and B2 thymomas. These types of thymomas hold a significant number of CD4(+)CD8(+) double-positive T cells, and at the same time, the neoplastic epithelial cells express HLA-DR molecules at a slightly reduced level compared with the normal thymus. The impaired expression of HLA-DR molecules in neoplastic epithelial cells of thymomas possibly affects positive selection of CD4(+)CD8(-) single-positive T cells and may result in alteration of its repertoire. The function of thymoma neoplastic cells as the cortical epithelium of the thymus and the morphological resemblance of thymomas to the cortex suggest that thymoma is of cortical epithelial origin; this might imply that thymoma lacks the functional medulla where professional antigen-presenting cells are engaged in negative selection. These findings suggest that thymoma generates autoreactive T cells causing autoimmunity. Further investigation on immunological function of thymoma is supposed to elucidate the pathogenesis of thymoma-related autoimmunity and the high affinity of thymoma with myasthenia gravis. In addition, studying the biology of thymoma is also expected to contribute to further understanding of T-cell development and immunological tolerance in the human, because thymoma can be considered an acquired thymus.

Entities:  

Mesh:

Year:  2008        PMID: 18401674     DOI: 10.1007/s11748-007-0185-8

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  28 in total

Review 1.  The generation and fate of thymocytes.

Authors:  K Shortman; M Egerton; G J Spangrude; R Scollay
Journal:  Semin Immunol       Date:  1990-01       Impact factor: 11.130

Review 2.  Early events in T-cell maturation.

Authors:  B Adkins; C Mueller; C Y Okada; R A Reichert; I L Weissman; G J Spangrude
Journal:  Annu Rev Immunol       Date:  1987       Impact factor: 28.527

Review 3.  Myasthenia gravis.

Authors:  J Lindstrom; D Shelton; Y Fujii
Journal:  Adv Immunol       Date:  1988       Impact factor: 3.543

4.  Delimitation of the proliferative stages in the human thymus indicates that cell expansion occurs before the expression of CD3 (T cell receptor).

Authors:  L Alvarez-Vallina; A González; F Gambón; M Kreisler; F Díaz-Espada
Journal:  J Immunol       Date:  1993-01-01       Impact factor: 5.422

5.  Characterization of CD4+ single positive cells that lack CD3 in the human thymus.

Authors:  Y Takeuchi; Y Fujii; M Okumura; K Inada; K Nakahara; H Matsuda
Journal:  Cell Immunol       Date:  1993-10-15       Impact factor: 4.868

Review 6.  Immunology of acetylcholine receptors in relation to myasthenia gravis.

Authors:  A Vincent
Journal:  Physiol Rev       Date:  1980-07       Impact factor: 37.312

7.  Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis.

Authors:  C Buckley; D Douek; J Newsom-Davis; A Vincent; N Willcox
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

8.  The immunologic role of thymectomy in the treatment of myasthenia gravis: implication of thymus-associated B-lymphocyte subset in reduction of the anti-acetylcholine receptor antibody titer.

Authors:  Meinoshin Okumura; Mitsunori Ohta; Yukiyasu Takeuchi; Hiroyuki Shiono; Masayoshi Inoue; Kenjiro Fukuhara; Yoshihisa Kadota; Shinichiro Miyoshi; Yoshitaka Fujii; Hikaru Matsuda
Journal:  J Thorac Cardiovasc Surg       Date:  2003-12       Impact factor: 5.209

9.  Human thymoma: immunologic characteristics of the lymphocytic component.

Authors:  L Lauriola; N Maggiano; M Marino; A Carbone; M Piantelli; P Musiani
Journal:  Cancer       Date:  1981-11-01       Impact factor: 6.860

10.  Neoplastic thymic epithelial cells of human thymoma support T cell development from CD4-CD8- cells to CD4+CD8+ cells in vitro.

Authors:  M Inoue; Y Fujii; M Okumura; Y Takeuchi; H Shiono; S Miyoshi; H Matsuda; R Shirakura
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

View more
  28 in total

1.  Genomic Analysis of Thymic Epithelial Tumors Identifies Novel Subtypes Associated with Distinct Clinical Features.

Authors:  Hyun-Sung Lee; Hee-Jin Jang; Rohan Shah; David Yoon; Masatsugu Hamaji; Ori Wald; Ju-Seog Lee; David J Sugarbaker; Bryan M Burt
Journal:  Clin Cancer Res       Date:  2017-04-11       Impact factor: 12.531

2.  Diminished regulatory T cells in cutaneous lesions of thymoma-associated multi-organ autoimmunity: a newly described paraneoplastic autoimmune disorder with fatal clinical course.

Authors:  T Hanafusa; H Azukizawa; S Kitaba; H Murota; N Umegaki; M Terao; S Sano; T Nakagiri; M Okumura; I Katayama
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

3.  New onset of myasthenia gravis 10 years after proton beam therapy for thymoma.

Authors:  Takahiro Karasaki; Tomohiro Murakawa; Kazuhiro Nagayama; Jun-Ichi Nitadori; Masaki Anraku; Yoshinao Kikuchi; Aya Shinozaki-Ushiku; Hiroshi Igaki; Jun Nakajima
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-10-10

Review 4.  Thymic malignancies: from clinical management to targeted therapies.

Authors:  Ronan J Kelly; Iacopo Petrini; Arun Rajan; Yisong Wang; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2011-11-21       Impact factor: 44.544

Review 5.  Thymoma and autoimmunity.

Authors:  Shahar Shelly; Nancy Agmon-Levin; Arie Altman; Yehuda Shoenfeld
Journal:  Cell Mol Immunol       Date:  2011-02-14       Impact factor: 11.530

Review 6.  Expression of cell cycle and apoptosis regulators in thymus and thymic epithelial tumors.

Authors:  Alexandra Papoudou-Bai; Alexandra Barbouti; Vassiliki Galani; Kalliopi Stefanaki; Dimitra Rontogianni; Panagiotis Kanavaros
Journal:  Clin Exp Med       Date:  2015-03-21       Impact factor: 3.984

Review 7.  The thymus and the immune system: layered levels of control.

Authors:  Diana K Lee; Frances T Hakim; Ronald E Gress
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

8.  Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies.

Authors:  Giovannella Palmieri; Carlo Buonerba; Piera Federico; Luigi Formisano; Lucia Nappi; Giuseppe Di Lorenzo; Mirella Marino; Vincenzo Damiano
Journal:  World J Clin Oncol       Date:  2012-07-10

9.  Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database.

Authors:  Sukhmani K Padda; Xiaopan Yao; Alberto Antonicelli; Jonathan W Riess; Yue Shang; Joseph B Shrager; Robert Korst; Frank Detterbeck; James Huang; Bryan M Burt; Heather A Wakelee; Sunil S Badve
Journal:  J Thorac Oncol       Date:  2017-11-27       Impact factor: 15.609

10.  A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors.

Authors:  Iacopo Petrini; Paul S Meltzer; In-Kyu Kim; Marco Lucchi; Kang-Seo Park; Gabriella Fontanini; James Gao; Paolo A Zucali; Fiorella Calabrese; Adolfo Favaretto; Federico Rea; Jaime Rodriguez-Canales; Robert L Walker; Marbin Pineda; Yuelin J Zhu; Christopher Lau; Keith J Killian; Sven Bilke; Donna Voeller; Sivanesan Dakshanamurthy; Yisong Wang; Giuseppe Giaccone
Journal:  Nat Genet       Date:  2014-06-29       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.